Navigation Links
Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research
Date:7/19/2011

INDIANAPOLIS, July 19, 2011 /PRNewswire/ -- Data were presented today from the first of two Phase III trials of semagacestat, including data from a 32 week follow-up period after dosing was halted in August 2010. Semagacestat is a gamma secretase inhibitor that had been studied as a potential treatment for Alzheimer's disease. Results shown today provided patient outcomes from the active treatment portion of the study and from a modified portion of the study conducted after dosing with semagacestat was stopped. Lilly presented the data during a plenary session at the Alzheimer's Association International Conference 2011 (AAIC 2011) in Paris, France.

The dosing in both semagacestat trials was halted in August 2010 because preliminary results from the two Phase III trials showed semagacestat did not slow Alzheimer's disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. Lilly continued to gather data, including cognitive scores, for 32 weeks after dosing was stopped.

"When we made the decision to halt dosing in the trials, we committed to collecting this data in an effort to benefit future Alzheimer's research and to provide safety follow-up for the patients," said Eric Siemers, M.D., senior medical director for the Alzheimer's Disease Team at Eli Lilly and Company. "We have a great deal of appreciation and respect for the dedication of the patients and caregivers who remained committed to the semagacestat trials from the beginning until these follow-up data were collected. By obtaining this information, future research efforts can be guided much more effectively."  

The study data confirmed preliminary results that showed that during the period of dosing, patients receiving semagacestat declined at a greater rate than patients taking placebo. During the follow-up period after dosing was halted, the cognitive and functional deficits of the patients in
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lillys Beamline Capabilities
2. Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
3. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
4. Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System
5. Lilly Quality Leader Walsh Appointed to Companys Executive Committee
6. Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations
7. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
8. Lilly Declares Third-Quarter 2011 Dividend
9. Lilly for Better Health™ Launches Enhanced Multi-Channel Patient Education Platform
10. Synthes and Lilly Sign Development and Collaboration Agreement
11. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
(Date:5/21/2013)... , May 21, 2013  BioRestorative Therapies, Inc. ... sciences company focused on developing stem cell based therapies ... Weinreb , its President and CEO, will be ... The conference will be held on Thursday, May 30, ... E 42nd Street in New York City.  Mr. Weinreb,s ...
(Date:5/21/2013)... STAAR Surgical Company (NASDAQ: STAA ... invasive ophthalmic products, today announced that it will participate ... recent financial results and business developments with investors and ... the 38 th Annual Deutsche Bank 2013 Healthcare ... Westin Waterfront Hotel on Wednesday, May 29, 2013 at ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3STAAR Surgical To Present At Upcoming Investor Conferences 2
... Medical,Technologies, Inc. (Nasdaq: RMTI ), a ... specialty pharmaceuticals focused on the end-,stage-renal-disease market ... in its Phase IIb dose-ranging study for ... drug. The Phase IIb dose-ranging study ...
... WHITE PLAINS, N.Y., Sept. 18 Millennium ... an interim analysis of a large,randomized, international ... in combination with Velcade(R) (bortezomib) showed that ... better. These patients, who are not,eligible for ...
Cached Medicine Technology:Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients 2
(Date:5/21/2013)... May 21, 2013 The Special Olympics Missouri ... coaches from across the state to Columbia. This state-level event ... University of Missouri and Columbia College, and at Hickman High ... Summer Games officially kick off at 7:30 p.m. Friday, May ... a Go Wild! theme, the Parade of Athletes, the culmination ...
(Date:5/21/2013)... Puroast® Low Acid Coffee has named ... Chairman of the Board. , Among the ... Johnson during his more than 30-year career was as ... Worldwide Chairman of Consumer Pharmaceuticals & Nutritionals and President ... develop and build the market for such brands as ...
(Date:5/21/2013)... VA, May 21, 2013The Journal of the ... today released its June issue, which includes a ... Pediatric Drug-Resistant Tuberculosis. It establishes standardized definitions, ... research. This is the first step as ... visibility and share evidence and resources that can ...
(Date:5/21/2013)... May 21, 2013 Children with autism showed significant ... home using everyday items such as scents, spoons and ... that a treatment known as environmental enrichment led to ... 3 and 12. Results appear online in Behavioral ... Leon randomly assigned 28 boys to one of two ...
(Date:5/21/2013)... meeting of ESHRE (European Society of Human Reproduction & ... medicine. Well over 9000 experts are expected this year, ... much of which is of great public interest. Reports ... good source of news and features. , This year,s ... in London from 7th to 10th July. , The ...
Breaking Medicine News(10 mins):Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 2Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 3Health News:Former Johnson & Johnson Executive Brian Perkins Named Chairman of Puroast® Coffee 2Health News:JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children 2Health News:JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children 3Health News:Enrichment therapy effective among children with autism, UCI study finds 2
... Body By Milk MVP, HOUSTON, Oct. 22 ... superstar athletes at Hightower High School. The,National Milk Mustache ... team has earned the title of Body By Milk ... part of the,first-ever nationwide Refuel Your School contest which ...
... Inc. is preparing for its next clinical trial of Cytolin, the breakthrough ... the virus. The preparations come at a time when CytoDyn, Inc. is ... expanded business activities. , ... (PRWEB) October 22, 2008 -- Although HIV ...
... with Super Antioxidant provides ... stress, ORLANDO, Fla., Oct. 21 ... India) are jointly introducing a,new organic dietary ... organic spirulina and astaxanthin in a single ...
... a method of assessing the quality of phase ... oncology conferences: EORTC-NCI-AACR (ENA) [1] and American Society ... Thursday (23 October) at the 20th ENA Symposium ... show there is room for improvement and the ...
... Capitol Hill Briefing, WASHINGTON, Oct. 21 ... and lured into prostitution as a result of ... girls are especially,vulnerable -- runaways, survivors of childhood ... developmental disability, or abuse,drugs/alcohol. They are crime victims, ...
... new moms participate, task force says , , TUESDAY, ... and health systems should encourage and promote breast-feeding, ... Services Task Force. , Members of the task ... interventions conducted in the United States and other ...
Cached Medicine News:Health News:Houston School Wins National got milk?(R) Refuel Your School Contest 2Health News:Houston School Wins National got milk?(R) Refuel Your School Contest 3Health News:CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS 2Health News:CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS 3Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 2Health News:Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as 'Lifestyle Support' for a Fast-Paced World 3Health News:Assessing the quality of phase I clinical trial abstracts 2Health News:Assessing the quality of phase I clinical trial abstracts 3Health News:The Hidden Crisis: Commercial Sexual Exploitation of Girls 2Health News:The Hidden Crisis: Commercial Sexual Exploitation of Girls 3Health News:Interventions to Promote Breast-Feeding Succeed 2
Ultrasonic Pachymeter UP-1000 is fast, accurate corneal thickness measurements....
... pachymeter, with compact LCD screen and optional ... portable, weighing slightly more than 2 lbs ... large liquid crystal display. The combination of ... fast precise algorithm enables measurement immediately upon ...
15 segment Vertical Prism Bar provides 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30 PD (Note: 30 PD is on the bar). 4447 xx Vertical Prism Bar....
Force 1C has a streamlined, compact design perfect for the requirements of outpatient surgery - as well as the power and performance features needed for a full range of general inpatient surgical pro...
Medicine Products: